| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/22/2006 | US20060134196 Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof |
| 06/22/2006 | US20060134194 Formulations containing substituted imidazole derivatives |
| 06/22/2006 | US20060134193 Method to improve pharmaceutical tablets having a matrix of cellulose ether |
| 06/22/2006 | US20060134192 Method of stabilizing diarylvinylene compound |
| 06/22/2006 | US20060134191 Immediate-release pharmaceutical dosage form comprising polymorphous tibolone |
| 06/22/2006 | US20060134190 Formulations of bisphosphonate drugs with improved bioavailability |
| 06/22/2006 | US20060134188 Transdermal pharmaceutical preparation with a progesterone A-specific ligand (PRASL) as active ingredient |
| 06/22/2006 | US20060134187 Method for treating inflammation associated with acne |
| 06/22/2006 | US20060134186 Oxygenating agents for enhancing host responses to microbial infections |
| 06/22/2006 | US20060134184 At least partially degradable films containing an active ingredient and method for the production of composition comprising an active compound |
| 06/22/2006 | US20060134182 Sphingolipids for improvement of the composition of the intestinal flora |
| 06/22/2006 | US20060134180 Encapsulated polyunsaturated fatty acids |
| 06/22/2006 | US20060134179 Health food product |
| 06/22/2006 | US20060134178 Composition containing organic substance having double bond with improved oxidative stability |
| 06/22/2006 | US20060134177 Amphiphilic block copolymers and their use |
| 06/22/2006 | US20060134176 Pharmaceutical delivery system and method of use |
| 06/22/2006 | US20060134175 Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use |
| 06/22/2006 | US20060134174 Pharmaceutical delivery system and method of use |
| 06/22/2006 | US20060134173 Polysiloxanes, method of synthesis and ophthalmic compositions |
| 06/22/2006 | US20060134168 Coatings with crystallized active agent(s) and methods |
| 06/22/2006 | US20060134155 Reducing fine lines and/or wrinkles in skin by applying an active agent: L-Theanine, S-Methyl-L-Cysteine or S-Phenyl-L-Cysteine to increase gene expression levels of: Beta-catenin, Collagen 4, Collagen 7, Frizzled 10, Estrogen Receptor alpha, and/or Hyaluronic acid synthase |
| 06/22/2006 | US20060134151 Novel sulfamide derivatives and cosmetic use thereof |
| 06/22/2006 | US20060134150 Submicron suspensions with polymorph control |
| 06/22/2006 | US20060134149 Methods for treatment of inflammatory diseases |
| 06/22/2006 | US20060134148 Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs |
| 06/22/2006 | US20060134147 reducing the formation of cellulite in skin by topically applying to the skin a composition having a cosmetically acceptable vehicle and an effective amount of carnitine creatinate |
| 06/22/2006 | US20060134146 pyrazine carboxamide compounds of sub-micron size; improve bioavailibility/absorption, exhibit no increase in size upon storage in the aqueous medium; N-(1-piperidinyl)-5,6-diphenyl-2-pyrazinecarboxamide; using a precipitation process without the need for water-immiscible solvent; obesity |
| 06/22/2006 | US20060134145 Propofol-containing fat emulsions |
| 06/22/2006 | US20060134144 Mucoadhesive composition and formulation for solubilization of insoluble drugs and preparation method thereof |
| 06/22/2006 | US20060134141 Glycoconjugate vaccines containing peptidoglycan |
| 06/22/2006 | US20060134130 Oral drug delivery compositions and methods |
| 06/22/2006 | US20060134117 Preventives/remedies for cancer |
| 06/22/2006 | US20060134115 Method of screening for sensitivity to kinase inhibitor therapy |
| 06/22/2006 | US20060134100 Dc-sign blockers and their use for preventing or treating viral infections |
| 06/22/2006 | US20060134095 Antioxidative composition and composition for external use |
| 06/22/2006 | US20060134091 Additive for an animal feed |
| 06/22/2006 | US20060134090 Method and dietary composition for improving lipid digestibility |
| 06/22/2006 | US20060134085 Compositions containing coenzyme q10 |
| 06/22/2006 | US20060134075 Composition and method for improving function of embryonic kidney transplants |
| 06/22/2006 | US20060134073 Compositions and methods for ex vivo preservation of blood vessels for vascular grafts using analogues of cAMP and cGMP |
| 06/22/2006 | US20060134064 Combined treatment with interferon-alpha and an epidermal growth factor receptor kinase inhibitor |
| 06/22/2006 | US20060134063 Agents for proliferating pancreatic beta-cells of the islets of langerhans, agents for suppressing apoptosis of said cells, and screening of candidate compounds for these agents |
| 06/22/2006 | US20060134062 Polymeric boronic acid derivatives as lipase inhibitors |
| 06/22/2006 | US20060134061 Bisacyloxypropylcysteine conjugates and the use thereof |
| 06/22/2006 | US20060134031 Phototherapy compositions and methods |
| 06/22/2006 | US20060134011 Oral and dental composition |
| 06/22/2006 | US20060134009 Low dose corticosteroid powders for inhalation |
| 06/22/2006 | US20060134008 Compositions and methods for pulmonary conditions |
| 06/22/2006 | US20060134006 Chemical carrier based on a beta-limit dextrin |
| 06/22/2006 | DE20321237U1 Pharmaceutical composition containing oxcarbazepine, having suitable release profile for once-daily administration in treatment of epilepsy, pain or alcohol withdrawal symptoms |
| 06/22/2006 | DE202005002324U1 Pharmazeutische Zusammensetzung zur Krebsbekämpfung Pharmaceutical composition for combating cancer |
| 06/22/2006 | DE19801821B4 Tuberkulozides Desinfektionsmittel Tuberculocidal disinfectant |
| 06/22/2006 | DE102004061593A1 Substituierte N-heterocyclische Verbindungen und ihre therapeutische Verwendung Substituted N-heterocyclic compounds and their therapeutic use |
| 06/22/2006 | DE102004061145A1 New glucopyranosyl-substituted benzene derivatives are sodium-dependent glucose cotransporter inhibitors, useful for treating e.g. metabolic disorders (type 1 and type 2 diabetes mellitus or metabolic acidosis) |
| 06/22/2006 | DE102004061017A1 Piperidinsulfonylharnstoffe und -thioharnstoffe, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate Piperidinsulfonylharnstoffe and thioureas, their preparation, their use and pharmaceutical compositions containing them |
| 06/22/2006 | DE102004061009A1 Substituierte 1,2,4-Triazin-5(2H)-one Substituted 1,2,4-triazine-5 (2H) -ones |
| 06/22/2006 | DE102004061008A1 3-Arylalkyl- und 3-Heteroarylalkyl-substituierte 1,2,4-Triazin-5(2H)-one 3-arylalkyl and heteroarylalkyl 3-substituted-1,2,4-triazine-5 (2H) -ones |
| 06/22/2006 | DE102004061006A1 3-Benzylthio-1,2,4-triazin-5(2H)-one 3-benzylthio-1,2,4-triazin-5 (2H) -ones |
| 06/22/2006 | DE102004061005A1 3-Cycloalkyl-1,2,4-triazin-5(2H)-one 3-cycloalkyl-1,2,4-triazin-5 (2H) -ones |
| 06/22/2006 | DE102004061003A1 New (5'S)-4'-cyclopentyl-3'-((S)-fluoro(4-(trifluormethyl)phenyl)meth yl)-2'-isopropyl-5',8'-dihydro-6'H-spiro(cyclobutane-1,T-quinoline)- 5'-ol is cholesterol transfer protein inhibitor useful for treating e.g. dyslipidemia and stroke |
| 06/22/2006 | DE102004061002A1 New (5'S)-2',4'-dicyclopentyl -3'-9(S)-fluoro(4-(trifluoromethyl) phenyl)methyl)-5',8' -dihydro-6'H-spiro(cyclopropane-1,7'-quinoline)- 5'-ol is a cholesterol ester transfer protein inhibitor useful for treating e.g. coronary heart diseases |
| 06/22/2006 | DE102004061001A1 New spiro-cyclohexyl-pyridine compound is cholesterol ester transfer protein inhibitor useful to treat and/or prevent coronary heart diseases, hypolipoproteinemia, dyslipidemia, hypertriglyceridemia, hyperlipidemia, restenosis and obesity |
| 06/22/2006 | DE102004061000A1 New tetrahydroquinoline compounds are cholesterol ester transfer protein inhibitors useful for primary and/or secondary prevention of coronary heart disease; and for treatment and/or prevention of e.g. hypolipoproteinemia and dyslipidemia |
| 06/22/2006 | DE102004060999A1 New (S)-4-cyclohexyl-3-((S)-fluoro-(4-trifluoromethyl-phenyl)-methyl) -2-isopropyl-7,7-dimethyl-5,6,7,8-tetrahydro-quinolin-5-ol is cholesterol ester transfer protein inhibitor useful e.g. to treat coronary heart disease |
| 06/22/2006 | DE102004060998A1 New 2,4-dicyclopentyl-3-(fluoro-(4-trifluoromethyl-phenyl)-methyl)-7, 7-dimethyl-5,6,7,8-tetrahydro-quinolin-5-ol compound is cholesterol ester transfer protein inhibitor useful to treat and/or prevent e.g. coronary heart diseases |
| 06/22/2006 | DE102004060997A1 New tetrahydroquinoline compounds are cholesterol ester transfer protein inhibitors useful for primary and/or secondary prevention of coronary heart disease; and for treatment and/or prevention of e.g. hypolipoproteinemia and dyslipidemia |
| 06/22/2006 | DE102004060984A1 New 4-heterocyclyl-benzamide derivatives, useful as antithrombotic agents for treating or preventing e.g. deep vein thrombosis or reocclusion after angioplasty, are inhibitors of factor Xa and other serine proteases |
| 06/22/2006 | DE102004060752A1 New heteroaryloxy-substituted phenylamino pyrimidine compounds are Rho-kinase inhibitors useful for the treatment and/or prophylaxis of cardiovascular diseases e.g. myocardial infarction and arrhythmia, erectile dysfunction and cancers |
| 06/22/2006 | DE102004060699A1 Verfahren zur Herstellung von Candesartan Process for the preparation of candesartan |
| 06/22/2006 | CA2675642A1 Process for the preparation of 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methyl piperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline, their intermediates and crystalline salts thereof |
| 06/22/2006 | CA2604463A1 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents |
| 06/22/2006 | CA2594987A1 Therapeutic agent for constipation |
| 06/22/2006 | CA2593031A1 Compositions comprising polymeric emulsifiers and methods of using same |
| 06/22/2006 | CA2592353A1 Tetrahydroisoquinoline compounds for treatment of cns disorders |
| 06/22/2006 | CA2592344A1 Expression vectors for treating bacterial infections |
| 06/22/2006 | CA2592321A1 Nicotinic acetylcholine receptor ligands |
| 06/22/2006 | CA2592288A1 Process for the preparation of galanthamine hydrobromide |
| 06/22/2006 | CA2591918A1 Cancer-specific spanx-n markers |
| 06/22/2006 | CA2591724A1 2-(phenyl or heterocyclic)-1h-phenantrho[9,10-d]imidazoles as mpges-1 inhibitors |
| 06/22/2006 | CA2591715A1 Agent for regulating bone formation |
| 06/22/2006 | CA2591621A1 Enantiomers of 3-heteroaryl-8h-8-azabicyclo(3.2.1)oct-2-ene and their use as monoamine neurotransmitter re-uptake inhibitors |
| 06/22/2006 | CA2591616A1 Diphenylurea derivatives useful as potassium channel activators |
| 06/22/2006 | CA2591582A1 Methods and compositions for induction or promotion of immune tolerance |
| 06/22/2006 | CA2591560A1 Amines, combination of amines and vanadium and amine vanadium salts for the treatment or prevention of dyslipidemia |
| 06/22/2006 | CA2591438A1 Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders |
| 06/22/2006 | CA2591430A1 Nicotinic acetylcholine receptor ligands |
| 06/22/2006 | CA2591416A1 Medicinal composition containing fbpase inhibitor |
| 06/22/2006 | CA2591415A1 N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenalin re-uptake inhibitors |
| 06/22/2006 | CA2591413A1 Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases |
| 06/22/2006 | CA2591412A1 Chromane derivatives useful as acid pump antagonists |
| 06/22/2006 | CA2591406A1 Pharmaceutical compounds and compositions |
| 06/22/2006 | CA2591405A1 Process for the preparation of pantoprazole sodium |
| 06/22/2006 | CA2591399A1 Aminocarboxylic acid derivative and medicinal use thereof |
| 06/22/2006 | CA2591397A1 4-cycloalkyl-substituted tetrahydrochinoline derivatives and use thereof as medicaments |
| 06/22/2006 | CA2591211A1 Thieno-pyridine derivatives as gaba-b allosteric enhancers |
| 06/22/2006 | CA2591123A1 Farnesyl protein transferase inhibitors and methods for treating proliferative diseases |
| 06/22/2006 | CA2591079A1 Bridged ring nk1 antagonists |
| 06/22/2006 | CA2591069A1 Benzisothiazole-1, 1-dioxide acting as antagonists to the vanilloid receptor subtype 1 (vr1) and uses thereof |
| 06/22/2006 | CA2591033A1 Heterocyclic aspartyl protease inhibitors |
| 06/22/2006 | CA2590979A1 Novel farnesyl protein transferase inhibitors and their use to treat cancer |